Kaiden DeFazio was born on March 20, 2015. At his four month checkup, his pediatrician noticed his weight was a little low. At his follow up appointment, she was extremely concerned with his development. She recommended he see a neurologist immediately.
It did not take long for the neurologist to make the diagnosis: “Kaiden has SMA. From his condition, I can almost guarantee it is Type 1 or Type 2. It is the number one killer of infants and in the worst case scenario, he may not have long to live, possibly as short as a month or two.”
Kaiden's neurologist and his team started working immediately to do all the tests that needed to be done in time for Kaiden to be part of an experimental study, which could possibly make him better or at least keep his SMA from getting worse.
As part of the double-blind study, Kaiden endured painful injections into his spinal cord with no anesthesia, and no assurance he was receiving the medicine. However, the study was successful. On December 23, 2016, Spinraza™ - the medicine in Kaiden’s experimental study – became the first treatment for SMA approved by the FDA. Now when Kaiden is receiving the treatments, it is with the knowledge that there is medicine in his injections. He is also able to have anesthesia during the injections.
Today Kaiden is happy toddler who is getting more and more mobile every day. He is currently enjoying his Panthera Micro Mini Wheelchair and loves being able to get around like other children.
While Spinraza™ is an exciting development, is not the final solution for those with SMA. It cannot reverse the effects of SMA that have already taken place, and while it works for Kaiden, it doesn’t work for everybody. There are also issues with pricing and access. But we are on the right path. More breakthroughs can happen at any time, and the Fighting For Kaiden Foundation will be among those supporting the search for a cure.